Canadian Paper Pushes Back On Biosimilar Switching
Brand-Backed Bodies’ Position Statement Expresses Caution
A joint position statement published by originator-backed bodies the Canadian Association of Gastroenterology and Crohn’s and Colitis Canada has expressed caution over so-called ‘non-medical switching’ of IBD patients from brand biologics to biosimilars.
You may also be interested in...
Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.
A body supported by biologic originators has attacked British Columbia’s move to switch Crohn’s and colitis patient to infliximab biosimilars, even though the resulting savings will be invested in patient care.
British Columbia’s move to switch gastrointestinal patients to biosimilar infliximabs by March 2020 has pleased local industry but upset an originator-backed patients’ group.